New trial aims to treat both liver damage and alcohol addiction at once

NCT ID NCT07060638

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study tests whether adding alcohol use disorder treatments (acamprosate and counseling) to standard liver therapy improves outcomes for people with severe alcohol-associated hepatitis. It also compares a new drug, F-652, against prednisone for liver treatment. About 216 adults aged 18-70 with severe liver inflammation and heavy alcohol use will participate. The goal is to see if the combined approach reduces death, liver complications, and return to drinking over 6 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

F-652 (IL-22), prednisone, acamprosate, and motivational interviewing

What this could lead to

If successful, this could point toward a combined treatment approach that improves both liver health and alcohol abstinence in people with severe alcohol-associated hepatitis.

What could go wrong

This is an early phase 2 trial with 216 participants, so results may not apply to everyone. The treatments may not improve outcomes or could cause side effects like infections or liver complications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse alcoholic hepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact

  • Indiana University

    RECRUITING

    Indianapolis, Indiana, 46202, United States

    Contact

  • Mayo Clinic

    RECRUITING

    Rochester, Minnesota, 55902, United States

    Contact

  • University of Louisville

    RECRUITING

    Louisville, Kentucky, 40292, United States

    Contact

  • University of Texas Southwestern Medical School

    RECRUITING

    Dallas, Texas, 15260, United States

    Contact

  • Virginia Commonwealth University

    RECRUITING

    Richmond, Virginia, 23284, United States

    Contact